1. Home
  2. ACRS vs ACU Comparison

ACRS vs ACU Comparison

Compare ACRS & ACU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRS
  • ACU
  • Stock Information
  • Founded
  • ACRS 2012
  • ACU 1867
  • Country
  • ACRS United States
  • ACU United States
  • Employees
  • ACRS N/A
  • ACU N/A
  • Industry
  • ACRS Biotechnology: Pharmaceutical Preparations
  • ACU Industrial Machinery/Components
  • Sector
  • ACRS Health Care
  • ACU Consumer Discretionary
  • Exchange
  • ACRS Nasdaq
  • ACU Nasdaq
  • Market Cap
  • ACRS 132.0M
  • ACU 155.9M
  • IPO Year
  • ACRS 2015
  • ACU N/A
  • Fundamental
  • Price
  • ACRS $4.32
  • ACU $41.66
  • Analyst Decision
  • ACRS Buy
  • ACU
  • Analyst Count
  • ACRS 6
  • ACU 0
  • Target Price
  • ACRS $7.20
  • ACU N/A
  • AVG Volume (30 Days)
  • ACRS 6.0M
  • ACU 17.5K
  • Earning Date
  • ACRS 11-06-2024
  • ACU 10-18-2024
  • Dividend Yield
  • ACRS N/A
  • ACU 1.45%
  • EPS Growth
  • ACRS N/A
  • ACU 188.89
  • EPS
  • ACRS N/A
  • ACU 4.84
  • Revenue
  • ACRS $27,079,000.00
  • ACU $190,488,947.00
  • Revenue This Year
  • ACRS N/A
  • ACU $5.34
  • Revenue Next Year
  • ACRS N/A
  • ACU $2.96
  • P/E Ratio
  • ACRS N/A
  • ACU $8.55
  • Revenue Growth
  • ACRS 26.35
  • ACU N/A
  • 52 Week Low
  • ACRS $0.77
  • ACU $32.85
  • 52 Week High
  • ACRS $5.17
  • ACU $50.99
  • Technical
  • Relative Strength Index (RSI)
  • ACRS 74.71
  • ACU 51.09
  • Support Level
  • ACRS $3.67
  • ACU $40.51
  • Resistance Level
  • ACRS $5.17
  • ACU $42.70
  • Average True Range (ATR)
  • ACRS 0.47
  • ACU 1.06
  • MACD
  • ACRS 0.20
  • ACU 0.08
  • Stochastic Oscillator
  • ACRS 72.93
  • ACU 74.38

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

About ACU Acme United Corporation.

Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.

Share on Social Networks: